Ipamorelin (2mg, 5mg)

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that acts as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. It is classified as a growth hormone releasing peptide (GHRP) and is distinguished in preclinical research by its high selectivity for growth hormone release with minimal stimulation of cortisol, prolactin, or adrenocorticotropic hormone (ACTH) — a selectivity profile that sets it apart from earlier GHRPs in its class.

What Is Ipamorelin?

Ipamorelin was developed as part of a research programme to identify the most selective GHSR agonists within the GHRP family. Earlier GHRPs (GHRP-2, GHRP-6) were found to stimulate GH release but also produced elevations in cortisol and prolactin — limiting their research utility in protocols requiring isolated GH stimulation. Ipamorelin’s selectivity profile addressed this limitation.

As a pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2), Ipamorelin is structurally compact, relatively stable, and has been among the most widely used GHRPs in both preclinical research and as a reference compound in GH secretagogue pharmacology.

Ipamorelin Research Background

Growth hormone secretion: Ipamorelin stimulates pulsatile GH release from the anterior pituitary via GHSR-1a agonism. Preclinical dose-response studies have characterised its GH-releasing potency, with research demonstrating effective GH stimulation at low doses with a short duration of effect (~2–3 hours) consistent with the pulsatile GH release pattern.

Selectivity profile: The defining characteristic in the research literature is Ipamorelin’s minimal effect on cortisol and ACTH at doses producing significant GH elevation. Studies directly comparing Ipamorelin to GHRP-2 and GHRP-6 have consistently documented this selectivity advantage, making it the preferred GHRP for research protocols where hormonal specificity is required.

Bone density research: Preclinical studies in rat models have examined Ipamorelin’s effects on bone mineral content and bone formation markers, with researchers observing increased bone growth in animal models — an area of ongoing investigation related to GH axis stimulation.

Gastrointestinal research: As a ghrelin receptor agonist, Ipamorelin has been studied in models of gastrointestinal motility. Research has examined its effects on gastric emptying and intestinal transit, relevant to its ghrelin-mimetic mechanism.

Ipamorelin + CJC-1295 No DAC Stack (Research)

The combination of Ipamorelin with CJC-1295 No DAC (Mod GRF 1-29) is the most researched GHRP/GHRH combination in the preclinical literature. The mechanistic rationale:

• CJC-1295 No DAC stimulates GH synthesis and release via GHRH receptors
• Ipamorelin provides a complementary, additive GH stimulus via GHSR-1a (ghrelin receptor)

The two pathways are independent and additive, which is why co-administration studies consistently report greater GH elevation than either compound alone. This combination is available pre-blended from VITALITY CARTEL.

Reconstitution Guidelines (Research Use)

Ipamorelin is supplied as lyophilised powder. Reconstitute with bacteriostatic water.

Recommended concentration: 1mg/ml to 2mg/ml.

For precise volume calculations: Peptide Reconstitution Calculator

Storage

• Lyophilised powder: 2–8°C, protected from light
• Reconstituted: 2–8°C, use within 28 days
• Long-term: -20°C

VITALITY CARTEL Ipamorelin

99%+ purity, HPLC verified. CoA available on request. Available as standalone 5mg vials and as a pre-blended CJC-1295/Ipamorelin combination. Domestic AU dispatch.